Abeona Therapeutics Inc. (ABEO)
| Market Cap | 188.19M |
| Revenue (ttm) | 7.00M |
| Net Income (ttm) | -84.84M |
| Shares Out | 93.77M |
| EPS (ttm) | -1.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $1.91 |
| Previous Close | $1.98 |
| Change ($) | -0.07 |
| Change (%) | -3.54% |
| Day's Open | 1.99 |
| Day's Range | 1.88 - 2.07 |
| Day's Volume | 2,165,849 |
| 52-Week Range | 1.02 - 4.08 |
Investors need to pay close attention to Abeona (ABEO) stock based on the movements in the options market lately.
NEW YORK and CLEVELAND, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that abstracts detailing ...
Investors need to pay close attention to Abeona (ABEO) stock based on the movements in the options market lately.
Abeona Therapeutics Inc's (NASDAQ: ABEO) stock does not reflect the company's in-house manufacturing capabilities and pipeline, according to Cantor Fitzgerald. The Abeona Therapeutics Analyst:...
Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of 38.46% and 0.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for th...
Conference call scheduled for Tuesday, November 10, 2020 at 8:30 a.m. ET Conference call scheduled for Tuesday, November 10, 2020 at 8:30 a.m. ET
NEW YORK and CLEVELAND, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso, Sen...
Steven H. Rouhandeh Appointed as Chairman of the Board of Directors
NEW YORK and CLEVELAND, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced changes in its executi...
NEW YORK and CLEVELAND, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company will ...
NEW YORK and CLEVELAND and DALLAS, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, and Taysha Gene Therapies, a...
Additional patients dosed in RDEB, MPS IIIA and MPS IIIB clinical programs
NEW YORK and CLEVELAND, July 10, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that two poster present...
Abeona (ABEO) restarts patient enrollment in phase III VIITAL study of EB-101 for the treatment of recessive dystrophic epidermolysis bullosa.
To lead Abeona’s commercial organization, EB-101 commercialization planning and pre-commercial strategy for AAV-based gene therapy programs To lead Abeona’s commercial organization, EB-101 com...
NEW YORK and CLEVELAND, July 08, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced recent updates on its c...
NEW YORK and CLEVELAND, June 18, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that two abstracts rela...
NEW YORK and CLEVELAND, June 17, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced Board of Director appoi...
Is (ABEO) Outperforming Other Medical Stocks This Year?
Abeona Therapeutics is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
Abeona's (ABEO) operating expenses are expected to have increased in the first quarter driven by clinical studies on its lead gene therapy candidate.
NEW YORK and CLEVELAND, April 21, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced it granted options to ...
As of late, it has definitely been a great time to be an investor in Abeona Therapeutics.
Company appoints experienced industry leaders Brian Pereira as Executive Chairman and Shawn Tomasello as Independent Board Member Company appoints experienced industry leaders Brian Pereira as...
Investors need to pay close attention to Abeona Therapeutics (ABEO) stock based on the movements in the options market lately.
Abeona Therapeutics (ABEO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
NEW YORK and CLEVELAND, March 27, 2020 (GLOBE NEWSWIRE) -- The COVID-19 pandemic has created extraordinary challenges across all aspects of healthcare. Many institutions and their brave staf...
Abeona Therapeutics (ABEO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Abeona (ABEO) treats first patient in a pivotal study evaluating its gene-corrected cell therapy, EB-101, as a treatment for recessive dystrophic epidermolysis bullosa, a rare connective tissu...
Majority of potential study participants have been pre-screened
Can these high-flying biotech stocks keep up their sizzling momentum?
Investors need to pay close attention to Abeona (ABEO) stock based on the movements in the options market lately.
The US dollar drew support from a healthy domestic economy, and Fed's cautiously optimistic stance about holding interest rates despite the coronavirus outbreak.
As of late, it has definitely been a great time to be an investor in Abeona Therapeutics.
Neurocognitive development of young MPS IIIA patients preserved up to two years post ABO-102 treatment
NEW YORK and CLEVELAND, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the United States ...
Study open for enrollment and patient screening underway at Stanford University
Abeona Therapeutics: Speculative Buy After Financing
NEW YORK and CLEVELAND, Dec. 24, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the closing of its unde...
The small-cap company announced the pricing of a public stock offering.
Investors need to pay close attention to Abeona Therapeutics (ABEO) stock based on the movements in the options market lately.
NEW YORK and CLEVELAND, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the pricing of its pub...
PRIME is sixth regulatory designation for the ABO-102 clinical program PRIME is sixth regulatory designation for the ABO-102 clinical program
NEW YORK and CLEVELAND, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it intends to offe...
FDA removes clinical hold; Company may proceed with VIITAL™ study
NEW YORK and CLEVELAND, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the presentations of da...
Sustained wound healing and favorable safety profile observed at three years post-treatment
Abeona Therapeutics Inc (NASDAQ: ABEO)'s market capitalization was growing by about two-thirds Tuesday following an announcement concerning the exploration of strategic options.
Abeona Therapeutics Inc. (ABEO) CEO João Siffert on Q2 2019 Results - Earnings Call Transcript
Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of -25.64% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the...
About ABEO
Abeona Therapeutics, a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten diseas... [Read more...]
| Industry Biotechnology | IPO Date Sep 19, 1980 |
| CEO Jeffrey Davis | Employees 88 |
| Stock Exchange NASDAQ | Ticker Symbol ABEO |
Analyst Forecasts
According to 6 analysts, the average rating for ABEO stock is "Buy." The 12-month stock price forecast is 5.00, which is an increase of 161.78% from the latest price.